Webinar February, 2016

Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models

Recorded February 10, 2016 

The recording of the webinar is available in full length here

Webinar Description:

Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.

Learning Objectives:

Uses of iPSC-derived cell types in screening/safety applications

Humanize drug discovery/development, "Mimic Clinic"

'Real-world' examples / case studies

Axiogenesis background / overview, products/services

 
Speakers:

Thomas Licher, PhD

Group Leader Lead Identification Technologies (LIT) Biology

Sanofi

 

Andrew Bruening-Wright, PhD

Principal Scientist Discovery, Charles River

Charles River

 

Ralf Kettenhofen, PhD

Head of Lab

Axiogenesis

 

Moderator:

Brian Murphy

Director Marketing & Sales

Axiogenesis

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10